Q-Line Biotech NSE SME IPO review

  • The company is engaged in the business of developing, manufacturing and marketing of diverse range of reagents and consumables.
  • It posted growth in its top lines for the reported periods, but suffered a setback for FY25 in bottom line following accounting adjustments.
  • As the company has no listed peers, it is trying to extract fancy price for its IPO.
  • Based on its overall financial data, the issue appears fully priced.
  • Well-informed investors may park moderate funds for long term.
Dilip Davda

About Company

Q-Line Biotech Ltd. (QBL) is engaged in the business of developing, manufacturing and marketing of diverse range of reagents (including kits and POC devices) & consumables and manufacturing, importing, distribution/supply of diagnostic equipment for different diagnostic healthcare needs. The company supplies diagnostic equipment and IVD products for different diagnostic healthcare needs since 2013 directly or through its distributor/s majorly to diagnostic service providers, hospitals and medical colleges. 

The company has established its brands over a period of 12 years through its experience, R & D, manufacturing capabilities and quality assurance. The core segments of operations of the Company in IVD Industry include Clinical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics and Others (POC Devices & Rapids).

QBL’s key manufacturing segments include indigenous manufacturing of reagents including Clinical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics and Others (POC Devices & Rapids) and supplying/ manufacturing of in-vitro diagnostics (IVD), Pathology equipment’s & devices. Further during the Covid-19 pandemic, the company diversified its focus and with the technical collaboration of third-party institutes and through its own R&D team developed a range of Covid testing kits viz. RT-PCR Kits, RNA Extraction Kits, VTM Kits etc.

It is research driven company engaged in developing and manufacturing a wide range of reagents formulations used across various IVD and diagnostic needs. The company leverages its R&D capabilities to develop and manufacture a portfolio of differentiated reagent formulations /products. Further, for its certain Class of Reagent & equipment’s and devices manufacturing business, the company has entered into technical collaboration with certain international companies. Under the agreement terms, it undertakes the manufacturing of these Reagent and equipment’s and devices as per the technical collaboration and specifications provided by the partners or companies. 

With the help of these collaborations the equipment and devices adhere to strict quality control, international standards and certifications. As of March 31, 2026, the company employed 19 personnel at R&D laboratories, which constituted 5.25% of its total permanent employee strength. As of March 31, 2026, it had 362 employees on its payroll and additional 223 contract employees in various departments.

Q-Line Biotech IPO

Issue Details / Capital History

The company is coming out with its maiden book building route IPO of 6253200 equity shares of Rs. 10 each to mobilize Rs. 214.48 cr. at the upper cap. The company has announced a price band of Rs. 326 - Rs. 343 per share.  The minimum application to be made is for 800 shares and in multiples of 400 shares thereon, thereafter. The IPO opens for subscription on May 21, 2026, and will close on May 25, 2026. The IPO constitute 26.81% of the post-IPO paid-up capital of the company. The shares will be listed on NSE SME Emerge. From the net proceeds of the IPO, it will utilize Rs. 93.50 cr. for working capital, Rs. 90.00 cr. for repayment/prepayment of certain borrowings, and the rest for general corporate purposes. 

The company raised Rs. 27.44 cr. in a pre-IPO placement of 800000 shares in May 2026, at Rs. 343 per share.

The IPO is jointly lead managed by Hem Securities Ltd., and Share India Capital Services Pvt. Ltd., Purva Sharegistry (India) Pvt. Ltd., is the registrar to the issue. HEM group’s Hem Finlease Pvt. Ltd., is the market maker as well as a syndicate member.

The company has issued initial equity capital at par value. It raised further equity shares in the price range of Rs. 125 – Rs. 417 between March 2019 and May 2026. It has also issued bonus shares in the ratio of 2 for 1 in March 2016, and 9 for 1 in August 2025. The average cost of acquisition of shares by the promoters is Rs. 0.00, Rs. 0.04, and Rs. 18.34 per share.

Post-IPO, company’s current paid-up equity capital of Rs. 17.07 cr. will stand enhanced to Rs. 23.33 cr. Based on the upper band of the IPO pricing, the company is looking for a market cap of Rs. 800.16 cr. 

IPO Lead Managers & Registrar

Financial Performance

On the financial performance front, for the last three fiscals, the company has (on a consolidated basis) posted total income/ net profit, of Rs. 184.81 cr. / Rs. 32.10 cr. (FY23), Rs. 206.45 cr. / Rs. 34.44 cr. (FY24), Rs. 322.58 cr. / Rs. 28.13 cr. (FY25). For 9M of FY26 ended on December 31, 2025, it earned a net profit of Rs. 38.69 cr. on a total income of Rs. 236.50 cr. Though it posted growth in its top lines for the reported periods, its bottom line posted inconsistency. For FY25, it posted lower net profit of Rs. 28.13 cr., and for 9M-FY26, though the top line is Rs, 236.50 cr. it posted bumper profit of Rs. 38.69 cr. in a pre-IPO period, that not only raise eyebrows, but also concern over its sustainability going forward. Despite higher other income for FY25, it marked lower net following extra-ordinary item of Rs. 16.97 cr. Its contingent liability stood at Rs. 61.64 cr. as of December 31, 2025, that raises alarm. Its overall borrowings of Rs. 242.57 cr. as of December 31, 2025, raise concern.

For the last two fiscals, the company has reported an average EPS of Rs. 25.00, and an average RoNW of 23.17%. The issue is priced at a P/BV of 2.44 based on its NAV of Rs. 140.81 per share as of December 31, 2025, but its post-IPO NAV data is missing from the offer documents.

If we attribute FY26 super earnings to its post-IPO fully diluted paid-up equity capital, then the asking price is at a P/E of 15.51, and based on FY25 earnings, the P/E stands at 28.44. The issue appears fully priced, based on its bumper earnings for 9M-FY26, which may not be sustained. 

For the reported periods, the company has posted PAT margins of 17.56% (FY23), 16.92% (FY24), 8.97% (FY25), 16.65% (9M-FY26), and RoCE margins of 22.14%, 19.25%, 17.66%, 13.32%, respectively, for referred periods.

All amounts in Indian Rupees crores

Period Ended Revenue Expense PAT Assets
2023 ₹184.81 ₹154.97 ₹32.10 ₹251.58
2024 ₹206.45 ₹175.85 ₹34.44 ₹339.25
2025 ₹322.58 ₹261.43 ₹28.13 ₹455.49
Dec 2025 ₹236.50 ₹186.96 ₹38.69 ₹561.34

Dividend Policy

The company has not paid any dividends for the reported periods of the offer document. It will adopt a prudent dividend policy, based on its financial performance and future prospects. 

Comparison with Listed Peers - for Fiscal 2025

As per the offer document, the company has no listed peers to compare with.

Name of the Company Face Value (₹) EPS basic (₹)Ā  EPS Diluted (₹) RONW (%) P/E Ratio NAV (₹)
Powerica Limited 5 15.26Ā  15.26 15.37 %Ā  24.45 99.76
Listed Peers
Cummins India Limited 2 72.15Ā  72.15 26.45% 64.13Ā  272.78
Kirloskar Oil Engines Limited 2 33.71 33.60 15.85% 43.24 212.60
NTPC Green Energy Limited 10 0.67 0.67 2.58% 129.40 21.88
Acme Solar Holdings Limited 2 4.55 4.53 5.59% 50.74Ā  74.54
Adani Green Energy Limited 10 8.37 8.37 11.90%Ā  101.53Ā  76.62
Disclaimer: Above table shows earnings and P/E ratio as of 2025-26

Merchant Banker's Track Record

The two merchant bankers associated with this issue have handled 79 issues in the past three years, out of which 8 issues closed below the issue price on listing date.

Conclusion - Apply for medium to long term

QBL is engaged in the business of developing, manufacturing and marketing of diverse range of reagents and consumables. It posted growth in its top lines for the reported periods, but suffered a setback for FY25 in bottom line following accounting adjustments. As the company has no listed peers, it is trying to extract fancy price for its IPO. Based on its overall financial data, the issue appears fully priced. Well-informed investors may park moderate funds for long term.

Dilip Davda is a veteran financial journalist associated with the Indian stock market since 1978. He has been contributing to print and electronic media on capital markets, insurance, and finance since 1985.

He is widely recognized for reviewing public issues and non-convertible debentures (NCDs) in the primary market. Drawing on over three decades of market experience and close interaction with merchant bankers, his reviews focus on detailed fundamental and financial analysis of companies, with a special emphasis on SME public issues.

Disclaimer: The information provided herein is solely for educational and informational purposes and does not constitute an offer, solicitation, or recommendation to buy or sell any securities. Readers are advised to consult a qualified financial advisor before making any investment decisions. Investments in the securities market are subject to market risks. The author does not intend to invest in the securities discussed.

FAQ Accordion
Q-Line Biotech IPO FAQs
1. What is Q-Line Biotech IPO? āŒ„
Q-Line Biotech IPO is SME IPO. The company is going to raise ₹214 Crores via IPO. The issue is priced at ₹326 to ₹343 per equity share. The IPO is to be listed on NSE SME.
2. When Q-Line Biotech IPO will open for subscription? āŒ„
The IPO is to open on May 21, 2026 for QIB, NII, and Retail Investors. The IPO will close on May 25,2026.
3. What is Q-Line Biotech IPO Investors Portion? āŒ„
The investors’ portion for QIB is 50%, NII is 15%, and Retail is 35%.
4. How to Apply the Q-Line Biotech IPO? āŒ„
You can apply for Q-Line Biotech IPO via ASBA online via your bank account. You can also apply for ASBA online via UPI through your stock brokers. You can also apply via your stock brokers by filling up the offline form.
5. What is Q-Line Biotech IPO Issue Size? āŒ„
Q-Line Biotech IPO issue size is ₹214 crores.
6. What is Q-Line Biotech IPO Price Band? āŒ„
Q-Line Biotech IPO Price Band is ₹326 to ₹343.
7. What is Q-Line Biotech IPO Lot Size? āŒ„
The minimum bid is 800 Shares with ₹2,74,400 amount.
8. What is the Q-Line Biotech IPO Allotment Date? āŒ„
Q-Line Biotech IPO allotment date is May 26,2026.
9. What is the Q-Line Biotech IPO Listing Date? āŒ„
Q-Line Biotech IPO listing date is May 29, 2026. The IPO is to list on NSE SME.

Lenskart Solutions IPO Review & Investor Guide

Lenskart Solutions IPO opens on October 31, 2025, and closes on November 4, 2025. The Lenskart Solutions IPO price band is set between ₹382 to ₹402 per share, with a face value of ₹2 each. As per the RHP, the company plans to raise around ₹7,278.02 crores through an IPO.
Lenskart Solutions IPO

For investors, it can be quite challenging to decide if the Lenskart Solutions IPO is a good investment or not. If you are unsure and still thinking about whether to apply or skip this IPO, don’t worry. In this article, we present the top key factors and a detailed review of the Lenskart Solutions IPO. This will help you analyze the strengths, risks, and financial details of the Lenskart Solutions IPO, making your investment decision better.

About Company 

Lenskart Solutions Limited, incorporated in 2008, is one of the leading technology-based eyewear companies engaged in designing, manufacturing, branding, and selling eyewear products. To them, a clear vision is essential for an individual’s well-being and personal growth. Their goal is to incorporate technology-enabled solutions that make quality and affordable ā€˜Eyewear for All’.

The company’s portfolio consists of a wide range of products, including prescription eyeglasses, sunglasses, contact lenses, and eyewear accessories. In FY25, according to the report, Lenskart is the largest seller of prescription eyeglasses. India is their largest market, and the company has expanded into selected international markets such as Japan, Southeast Asia, and the Middle East. 

The company mostly designs and sells its products under its own brand and sub-brands. As of March 31, 2025, the company consists of a 105-member design and merchandising team who are involved in designing eyeglasses, including both frames and lenses. They provide diversified eyewear products for all price ranges and age groups, targeting the needs of each customer. Moreover, in FY25, Lenskart had launched 105 new in-house designed collections worldwide, also collaborating with famous brands and celebrities. Its mobile app had over 100 million downloads, and it runs a total of 2,723 stores worldwide, 2,067 in India and 656 abroad as of March 31, 2025.

Strengths

  • The company consists of its own in-house frame and lens engineering and manufacturing capabilities, which allow it to design, produce, and deliver high-quality eyewear that serves the unique customer requirements.
  • Rather than just focusing on trends, Lenskart follows a customer-focused approach where they design their eyewear according to the customer’s needs, feedback, and preferences.
  • Through its Omnichannel Retail Network, Lenskart reaches its customers via both online and offline channels, making it convenient and accessible to all.
  • They aim to offer innovative, quality, affordable, and accessible eyewear for all, filling the gap within the eyewear industry. 

Weaknesses

  • The company makes some of its frames in China, as well as imports some raw materials from them. Meaning that any interruption or delay in this supply can badly affect the business, cash flow, and operations.
  • Over the last 3 years, the company has shown a low return on Equity (ROE) of 1.16% which indicates weak profitability.
  • The company’s Earnings include other income of ₹351 Crores, which refers to most of its profits coming from outside-business activities, and not from its main business. 
  • In the past, the company suffered from losses and only recently turned profitable.

Lenskart Solutions IPO Review 

ReviewerRecommendation
IPO WatchMay Apply
Axis Capital
Bajaj Financial Securities Limited
Capital MarketNeutral
Marwadi Shares and Finance LtdApply
SBICAP Securities LimitedApply
SMIFS LimitedApply
Ventura Securities LimitedApply
Canara Bank 
DRChoksey FinServ 
Emkay Global 
Hem Securities 
IDBI Capital 
Nirmal Bang 
Sharekhan 
SMC Global 
Sushil Finance 
Swastika Investmart 
Ventura Securities 
Geojit 
Reliance Securities 
BP Wealth 
ICICIdirect 
Choice Broking 

Lenskart Solutions IPO Details

IPO Open Date:October 31, 2025
IPO Close Date:November 4, 2025
Face Value:₹2 Per Equity Share
IPO Price Band:₹382 to ₹402 Per Share
Issue Size:₹7,278.02 Crores
Fresh Issue₹2,150 Crores
Offer-for-SaleUp to 12,75,62,573 equity shares
Registrar MUFG Intime India Pvt. Ltd.
IPO Lead ManagersKotak Mahindra Capital Co. Ltd.
Morgan Stanley India Co. Pvt. Ltd. 
Avendus Capital Pvt.Ltd.
Citigroup Global Markets India Pvt.Ltd.
Axis Capital Ltd.
Intensive Fiscal Services Pvt.Ltd.
Basis of AllotmentNovember 6, 2025
IPO Listing Date:November 10, 2025
Listing BSE, NSE

Financial Performance Trend Details 

Particulars30 Jun 202531 Mar 202531 Mar 2024
Total Income₹1,946.10 crores ā‚¹7,009.28 crores₹5,609.87 crores
EBITDA₹336.63 crores₹971.06 crores₹672.09 crores
Profit after Tax (PAT)₹61.17 crores₹297.34 crores₹-10.15 crores
Net Worth₹6,176.87 Crores₹6,108.30 Crores₹5,642.38 Crores
Reserve and Surplus₹5,855.43 Crores₹5,795.00 Crores₹5,466.50 Crores
Total Borrowings₹335.48 Crores₹345.94 Crores₹497.15 Crores

Peer Comparison with the Company

There are no listed companies in India or globally that operate in a similar business model to theirs.

Key Performance Indicator

KPIValues
ROCE13.84%
RoNW4.84%
EBITDA Margin14.60%
Price to Book Value 13.04
Market Capitalization69726.83

Promoters & Track Records, if any

  • Peyush Bansal, born on February 25, 1984, aged 41 years, is the Chairman, Managing Director, and Chief Executive Officer of the Company. He holds 173,222,220 of Equity Shares, representing 10.28% of pre-Offer paid-up Equity Share Capital in the company.
  • Neha Bansal, born on October 29, 1981, aged 43 years, is the Executive Director of the Company. She holds 128,271,184 of Equity Shares, representing 7.61% of pre-Offer paid-up Equity Share Capital in the company.
  • Amit Chaudhary was born on July 16, 1986, aged 39 years, and is the Executive Director of the Company. She holds 16,585,630 of Equity Shares, representing 0.98% of pre-Offer paid-up Equity Share Capital in the company.
  • Sumeet Kapahi was born on May 12, 1965, aged 60 years, and is the Global Head of Sourcing of the Company. He holds 16,107,050 of Equity Shares, representing 0.96% of pre-Offer paid-up Equity Share Capital in the company.

Expansion 

  • The proceeds raised from the fresh issue will be used towards the set-up of new CoCo stores in India.
  • A portion of the funds will be utilized for expenditures for lease/rent/license agreements, related payments for our CoCo stores operated by the Company.
  • Some funds will be used towards technology and cloud infrastructure.
  • A portion of it goes towards Brand marketing and business promotion expenses for enhancing brand awareness.
  • Lastly, the remaining funds will be used for unidentified inorganic acquisitions and general corporate purposes.

Lenskart Solutions IPO – Should You Apply or Not?

Lenskart Solutions boasts strong market leadership, an Omnichannel business model, consistent revenue growth, and technology-driven & customer-centric operations, positioning it well for long-term growth. While the Indian eyewear/optical market has significant growth potential, investors should also consider key risks such as competitive pressure, supply chain dependence, and high valuation. 

As of October 29, the GMP of Lenskart Solutions is ₹80, indicating a listing gain of around 18% to 22%. Short-term investors may apply for the IPO for listing gains, given attractive Grey Market Premium (GMP) trends and strong brand recall. Whereas Long-term investors must analyze the risks, high valuation, competitive pressure, and market sentiment before investing their money in it.

Please note:

Investors are advised to make their own decisions and apply entirely at their own risk. This article is written using information from the company’s RHP (Red Herring Prospectus) data and online sources. If you have any queries, kindly contact the IPO Watch Team.

Table of Contents

Picture of Jagat Joshi

Jagat Joshi

Founder of IPOWatch, brings nearly 15 years of experience in IPO analysis and market research. He provides complete coverage of upcoming IPOs, subscription trends, grey market premiums (GMP), and post-listing performance, along with easy-to-understand reviews, insights, and analysis. In his working journey, he has worked with various platforms and received expertise in stock market analysis and primary markets.
Picture of Jagat Joshi

Jagat Joshi